

Dermatol. 2007;156: 990-996), DVT and pulmonary embolism (Shimanovich I. et. al. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins Br J. Dermatol 2008;158:382-388) including death from septic shock (Tournadre A, et al. Polymyositis and pemphigus vulgaris in a patient successful treatment with rituximab Jt Bone Spine 2008;75:728-729). Accordingly, there is a need for new therapies that can treat PV effectively and related diseases without causing or at least reducing serious side effects compared to the standard of care in treating pemphigus.


**Summary**

In one aspect, the present disclosure provides ~~the~~ a use of a therapeutically effective amount of a BTK inhibitor ~~in place of or in combination with a corticosteroid~~ in the manufacture of a medicament~~,~~ for ~~treating an acute inflammatory and/or autoimmune disease~~the treatment of pemphigus vulgaris or pemphigus foliaceus in a mammal in need thereof, wherein said BTK inhibitor is used in place of, or in combination with, a corticosteroid therapy; ~~the corticosteroid is to be used as the first or second line therapy; and~~ optionally, said BTK inhibitor is to be administered in combination with a noncorticosteroidal immunosupressive and/or antiinflammatory agent; and wherein said BTK inhibitor is chosen from : AVL 263 and 293; GDC-0834; GDC0853; BMS-488516; BMS-509744; CGI-1746; CTA-056; HY-11066; ONO-WG37; PLS-123; RN486; HM71224; ABT-105/ABBV-105; AC0025; EBI-1266; MSC-2364447; PF-06250112; PF-303; RG7625;







RG7880; SNS-062; TP-4207; X-022; ;




;



;









;



;

Dermatol. 2007;156: 990-996), DVT and pulmonary embolism (Shimanovich I. et. al. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins Br J. Dermatol 2008;158:382-388) including death from septic shock (Tournadre A, et al. Polymyositis and pemphigus vulgaris in a patient successful treatment with rituximab Jt Bone Spine 2008;75:728-729). Accordingly, there is a need for new therapies that can treat PV effectively and related diseases without causing or at least reducing serious side effects compared to the standard of care in treating pemphigus.

**Summary**

In one aspect, the present disclosure provides a use of a therapeutically effective amount of a BTK inhibitor in the manufacture of a medicament for the treatment of pemphigus vulgaris or pemphigus foliaceus in a mammal in need thereof, wherein said BTK inhibitor is used in place of, or in combination with, a corticosteroid therapy; optionally, said BTK inhibitor is to be administered in combination with a noncorticosteroidal immunosupressive and/or antiinflammatory agent; and wherein said BTK inhibitor is chosen from : AVL 263 and 293; GDC-0834; GDC0853; BMS-488516; BMS-509744; CGI-1746; CTA-056; HY-11066; ONO-WG37; PLS-123; RN486; HM71224; ABT-105/ABBV-105; AC0025; EBI-1266; MSC-2364447; PF-06250112; PF-303; RG7625; RG7880; SNS-062; TP-4207; X-022;  ;  ;  ;  ;  ;  ;